Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics

Purpose of reviewPatients with acute myeloid leukemia (AML) and normal karyotype constitute the single largest cytogenetic group of AML, estimated to account for 45% of adults with de novo AML. This article critically reviews the recent literature that addresses the molecular heterogeneity of this group of patients and how this relates to prognostic stratification and novel therapeutic approaches. Recent findingsFour prognostic biomarkers-the internal tandem duplication and point mutations in the FLT3 gene, partial tandem duplication of the MLL gene, mutations of the CEBPA gene, and overexpression of the BAALC gene-have been found to predict outcome in patients with AML and normal cytogenetics. In addition, one study using gene expression profiling identified two subgroups of AML patients with a normal karyotype whose survival differs significantly. Because mutations in FLT3 result in an autophosphorylated, leukemogenesis-driving protein, molecular targeting therapy with a new class of tyrosine kinase inhibitors is being explored in early clinical trials. SummaryConsiderable progress has been made in molecular characterization of AML patients with normal cytogenetics. The challenge for the future is to incorporate these biologic discoveries into novel risk-adapted therapeutic strategies that will improve the currently disappointing cure rate (approximately 25-40%) of this group of patients.

[1]  K Wheatley,et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.

[2]  T. Lister,et al.  Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2 , 2003, Genes, chromosomes & cancer.

[3]  F. Lo‐Coco,et al.  Down-modulation of the C/EBPalpha transcription factor in core binding factor acute myeloid leukemias. , 2003, Blood.

[4]  Bob Löwenberg,et al.  Acute myeloid leukemia and acute promyelocytic leukemia. , 2003, Hematology. American Society of Hematology. Education Program.

[5]  F. Solé,et al.  Genetic diagnosis by comparative genomic hybridization in adult de novo acute myelocytic leukemia. , 2004, Cancer genetics and cytogenetics.

[6]  M. Meyerson,et al.  Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. , 2004, Blood.

[7]  J. Tchinda,et al.  Spectral karyotyping and fluorescence in situ hybridization detect novel chromosomal aberrations, a recurring involvement of chromosome 21 and amplification of the MYC oncogene in acute myeloid leukaemia M2 , 2001, British journal of haematology.

[8]  G. Ehninger,et al.  Analysis of Flt3-activating Mutations in 979 Patients with Acute Myelogenous Leukemia: Association with Fab Subtypes and Identification of Subgroups with Poor Prognosis , 2022 .

[9]  F. Cavalli,et al.  A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. , 2003, Blood.

[10]  M. Levis,et al.  Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression. , 2004, Blood.

[11]  C. Bloomfield,et al.  Cytogenetics in acute leukemia. , 2004, Blood reviews.

[12]  H. Kantarjian,et al.  Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. , 2004, Blood.

[13]  D. Tenen,et al.  Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Radich,et al.  Novel FLT3 point mutations within exon  14 found in patients with acute myeloid leukaemia , 2004, British journal of haematology.

[15]  N. Villamor,et al.  Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells , 2003, Leukemia.

[16]  C. Bloomfield,et al.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.

[17]  A. de la Chapelle,et al.  Cytogenetic studies of 103 patients with acute myelogenous leukemia in relapse. , 1989, Cancer genetics and cytogenetics.

[18]  F. Ravandi,et al.  Molecular identification of CBFβ-MYH11 fusion transcripts in an AML M4Eo patient in the absence of inv16 or other abnormality by cytogenetic and FISH analyses – a rare occurrence , 2003, Leukemia.

[19]  M. Caligiuri,et al.  Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. , 1998, Cancer research.

[20]  M. Caligiuri,et al.  BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  R. Eils,et al.  A cryptic t(5;11)(q35;p15.5) in 2 children with acute myeloid leukemia with apparently normal karyotypes, identified by a multiplex fluorescence in situ hybridization telomere assay. , 2002, Blood.

[22]  A. Hagemeijer,et al.  FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress. , 2003, Blood.

[23]  M. Caligiuri,et al.  BAALC, a novel marker of human hematopoietic progenitor cells. , 2003, Experimental hematology.

[24]  Torsten Haferlach,et al.  AML1–ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia , 2001, Nature Medicine.

[25]  M. Slovak,et al.  Twenty‐four‐color spectral karyotyping reveals chromosome aberrations in cytogenetically normal acute myeloid leukemia , 2000, Genes, chromosomes & cancer.

[26]  S. Fröhling,et al.  Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. Caligiuri,et al.  Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  F. Lu,et al.  The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. , 2004, Molecular cell.

[29]  S. Fröhling,et al.  CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  尾関 和貴.  Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia , 2005 .

[31]  T. Kummalue,et al.  Cell cycle inhibition mediated by the outer surface of the C/EBPα basic region is required but not sufficient for granulopoiesis , 2003, Oncogene.

[32]  J. Cayuela,et al.  Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). , 2002, Blood.

[33]  Axel Benner,et al.  Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. , 2002, Blood.

[34]  H. Kantarjian,et al.  SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. , 2003, Blood.

[35]  G. Ehninger,et al.  Comparison of spectral karyotyping and conventional cytogenetics in 39 patients with acute myeloid leukemia and myelodysplastic syndrome , 2000, Leukemia.

[36]  C. Bloomfield,et al.  Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Pu Zhang,et al.  Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia , 2001, Nature Genetics.

[38]  R. Tibshirani,et al.  Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. , 2004, The New England journal of medicine.

[39]  U. Jaeger,et al.  Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16). , 2002, The hematology journal : the official journal of the European Haematology Association.

[40]  Carl W. Miller,et al.  Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. , 2002, Blood.

[41]  Sandya Liyanarachchi,et al.  Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[42]  J. Downing,et al.  Gene Expression Profiling of Pediatric Acute Myelogenous Leukemia Materials and Methods , 2022 .

[43]  D. Tenen,et al.  CCAAT/Enhancer Binding Protein α Is a Regulatory Switch Sufficient for Induction of Granulocytic Development from Bipotential Myeloid Progenitors , 1998, Molecular and Cellular Biology.

[44]  U. Germing,et al.  Hidden chromosomal aberrations are rare in primary myelodysplastic syndromes with evolution to acute myeloid leukaemia and normal cytogenetics. , 2004, Leukemia research.

[45]  M. Caligiuri,et al.  Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. , 2001, Cancer research.

[46]  B. Calabretta,et al.  Transcription activation function of C/EBPalpha is required for induction of granulocytic differentiation. , 2003, Blood.

[47]  A. Jauch,et al.  Cryptic chromosomal aberrations leading to an AML1/ETO rearrangement are frequently caused by small insertions , 2003, Genes, chromosomes & cancer.

[48]  D. Tenen,et al.  The amino terminal and E2F interaction domains are critical for C/EBP alpha-mediated induction of granulopoietic development of hematopoietic cells. , 2003, Blood.

[49]  G. Ehninger,et al.  Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia , 2003, Genes, chromosomes & cancer.

[50]  Bob Löwenberg,et al.  Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. , 2003, The hematology journal : the official journal of the European Haematology Association.

[51]  M. Caligiuri,et al.  ALL-1 partial duplication in acute leukemia. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[52]  M. Caligiuri,et al.  Molecular rearrangement of the ALL-1 gene in acute myeloid leukemia without cytogenetic evidence of 11q23 chromosomal translocations. , 1994, Cancer research.

[53]  R. Verhaak,et al.  Prognostically useful gene-expression profiles in acute myeloid leukemia. , 2004, The New England journal of medicine.

[54]  M. Slovak,et al.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study , 2000 .

[55]  Martin Dugas,et al.  Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. , 2002 .

[56]  J. Radich,et al.  The role of FLT3 in haematopoietic malignancies , 2003, Nature Reviews Cancer.

[57]  A. Viale,et al.  Induction of C/EBPalpha activity alters gene expression and differentiation of human CD34+ cells. , 2003, Blood.

[58]  W. Hiddemann,et al.  Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML , 2000, Leukemia.

[59]  W. Hiddemann,et al.  Analysis of FLT 3 length mutations in 1003 patients with acute myeloid leukemia : correlation to cytogenetics , FAB subtype , and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease , 2002 .

[60]  S. Fröhling,et al.  Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  M. Caligiuri,et al.  BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. , 2003, Blood.

[62]  J. Hess.  MLL: a histone methyltransferase disrupted in leukemia. , 2004, Trends in molecular medicine.